Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

L-Ornithine is a non-essential amino acid that plays a central role in the urea cycle — the primary pathway for ammonia detoxification in the liver. As a precursor to citrulline, proline, and polyamines, ornithine also contributes to nitric oxide production and wound healing. Its primary supplement applications are for exercise-related fatigue reduction (through ammonia clearance), sleep quality improvement, and liver detoxification support. Often combined with arginine or aspartate to enhance the urea cycle.

Studied Dose 2–6 g/day; fatigue reduction: 2 g before exercise; sleep: 400 mg before bedtime; liver applications: 3–9 g/day ornithine aspartate (LOLA) under medical supervision
Active Compound L-Ornithine (free-form amino acid) or L-Ornithine HCl — often combined as Ornithine alpha-ketoglutarate (OKG) or ornithine aspartate (LOLA) for clinical applications

Exercise fatigue reduction via ammonia clearance

Ornithine supplementation significantly reduces exercise-induced fatigue by enhancing ammonia clearance through the urea cycle. Ammonia accumulation during intense exercise is a primary driver of central and peripheral fatigue. A Japanese RCT showed ornithine (2 g/day) significantly reduced subjective fatigue scores and ammonia levels following moderate exercise.

Sleep quality improvement

A small but well-designed RCT demonstrated ornithine (400 mg at bedtime) significantly improved sleep quality, reduced sleep onset latency, and improved next-day stress markers in healthy adults. The proposed mechanism involves ornithine's role in GABA metabolism and melatonin pathway modulation.

Growth hormone secretion support

High-dose ornithine (170 mg/kg body weight) stimulates growth hormone secretion in clinical studies — though the doses required are very high (well above practical supplement levels) and GI side effects are common. Lower doses (2–5 g) used in sports supplements may have modest GH-stimulating effects when combined with exercise.

Liver ammonia detoxification

Ornithine aspartate (LOLA) is an established pharmaceutical treatment for hepatic encephalopathy — the neurological condition caused by ammonia accumulation in liver failure. Ornithine drives the urea cycle, while aspartate supports the glutamate-glutamine ammonia buffering system, together reducing blood ammonia in cirrhotic patients.

1

Urea cycle central metabolite

Ornithine is the cyclic carrier in the urea cycle — accepting carbamoyl phosphate (from ammonia + CO2) to form citrulline in the mitochondria, which is then converted to argininosuccinate, arginine, and finally urea for renal excretion. By providing ornithine substrate, supplementation increases the rate of ammonia conversion to non-toxic urea, reducing ammonia accumulation during exercise or liver stress.

2

Polyamine synthesis for cellular growth

Ornithine decarboxylase (ODC) converts ornithine to putrescine — the first step in polyamine synthesis (putrescine → spermidine → spermine). Polyamines are essential for cell proliferation, DNA stabilization, and wound healing. This pathway explains ornithine's role in tissue repair and the growth-promoting effects observed in trauma and surgical recovery studies.

3

Proline and collagen synthesis precursor

Ornithine is converted to proline via pyrroline-5-carboxylate — providing substrate for collagen synthesis and wound healing. This pathway gives ornithine significance in recovery from physical trauma, surgery, and exercise-induced tissue microtrauma.

1
L-Ornithine and Exercise Fatigue — RCT
PubMed

Randomized, double-blind, placebo-controlled trial of L-ornithine hydrochloride (2 g/day) vs. placebo in 45 healthy adults performing moderate treadmill exercise for 2 weeks.

45 healthy adults. 2-week exercise + supplementation protocol.

Ornithine significantly reduced fatigue sensation scores, reduced blood ammonia levels post-exercise, and improved fat oxidation efficiency. Subjective fatigue ratings significantly lower. Supports ornithine for exercise fatigue management through urea cycle enhancement.

2
L-Ornithine and Sleep Quality — RCT
PubMed

Randomized, double-blind, placebo-controlled crossover trial of ornithine (400 mg at bedtime) vs. placebo in 52 healthy adults with mild fatigue and sleep complaints.

52 healthy adults with sleep concerns. 8-week crossover design.

Ornithine significantly improved sleep quality scores, reduced sleep onset time, and improved morning stress markers vs. placebo. Cortisol/DHEA ratio improved. Well-tolerated with no adverse effects.

Common Potential side effects

Generally well tolerated at supplemental doses (2–6 g/day)
GI effects (nausea, diarrhea) at high doses (>10 g/day)
Not recommended in urea cycle disorders — ornithine transcarbamylase deficiency contraindication

Important Drug interactions

No established significant pharmacokinetic drug interactions at standard supplemental doses
Liver medications — LOLA form used medically for hepatic encephalopathy; coordinate with physician if on liver disease medications
Arginine — synergistic urea cycle effects; commonly combined